Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC)

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 May 25

PMID 38791885

Authors

Teresa Del Giudice

Nicoletta Staropoli

Pierfrancesco Tassone

Pierosandro Tagliaferri

Vito Barbieri

Affiliations

Soon will be listed here.

Abstract

Despite the recent availability of immune checkpoint inhibitors, not all patients affected by Non-Small-Cell Lung Cancer (NSCLC) benefit from immunotherapy. The reason for this variability relies on a variety of factors which may allow for the identification of novel biomarkers. Presently, a variety of biomarkers are under investigation, including the PD1/PDL1 axis, the tumor mutational burden, and the microbiota. The latter is made by all the bacteria and other microorganisms hosted in our body. The gut microbiota is the most represented and has been involved in different physiological and pathological events, including cancer. In this light, it appears that all conditions modifying the gut microbiota can influence cancer, its treatment, and its treatment-related toxicities. The aim of this review is to analyze all the conditions influencing the gut microbiota and, therefore, affecting the response to immunotherapy, iRAEs, and their management in NSCLC patients. The investigation of the landscape of these biological events can allow for novel insights into the optimal management of NSCLC immunotherapy.

Citing Articles

Microbiota and Cytokine Modulation: Innovations in Enhancing Anticancer Immunity and Personalized Cancer Therapies.

Rad H, Tahmasebi H, Javani S, Hemati M, Zakerhamidi D, Hosseini M Biomedicines. 2025; 12(12.

PMID: 39767682 PMC: 11673251. DOI: 10.3390/biomedicines12122776.

Biomarkers for immunotherapy resistance in non-small cell lung cancer.

Rother C, John T, Wong A Front Oncol. 2025; 14:1489977.

PMID: 39749035 PMC: 11693593. DOI: 10.3389/fonc.2024.1489977.

A two-step, two-sample Mendelian randomization analysis investigating the interplay between gut microbiota, immune cells, and melanoma skin cancer.

Lou J, Xiang Z, Zhu X, Fan Y, Li J, Jin G Medicine (Baltimore). 2024; 103(45):e40432.

PMID: 39533622 PMC: 11557063. DOI: 10.1097/MD.0000000000040432.

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer.

Hansen T, Hill J, Tincknell G, Siu D, Brungs D, Clingan P Explor Target Antitumor Ther. 2024; 5(6):1247-1260.

PMID: 39465010 PMC: 11502072. DOI: 10.37349/etat.2024.00273.

Impact of the Lung Microbiota on Development and Progression of Lung Cancer.

Belaid A, Romeo B, Rignol G, Benzaquen J, Audoin T, Vouret-Craviari V Cancers (Basel). 2024; 16(19).

PMID: 39409962 PMC: 11605235. DOI: 10.3390/cancers16193342.

References

Huemer F, Rinnerthaler G, Westphal T, Hackl H, Hutarew G, Gampenrieder S . Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. Oncotarget. 2018; 9(23):16512-16520. PMC: 5893258. DOI: 10.18632/oncotarget.24751. View

Vihinen H, Jokinen A, Laajala T, Wahid N, Peltola L, Kettunen T . Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy. Clin Lung Cancer. 2023; 24(4):295-304. DOI: 10.1016/j.cllc.2023.01.004. View

Cortellini A, Di Maio M, Nigro O, Leonetti A, Cortinovis D, Aerts J . Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021; 9(4). PMC: 8031700. DOI: 10.1136/jitc-2021-002421. View

Xin Y, Liu C, Zang D, Chen J . Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer. Front Immunol. 2024; 15:1343450. PMC: 10867196. DOI: 10.3389/fimmu.2024.1343450. View

Souza V, Forder A, Pewarchuk M, Telkar N, de Araujo R, Stewart G . The Complex Role of the Microbiome in Non-Small Cell Lung Cancer Development and Progression. Cells. 2023; 12(24). PMC: 10741843. DOI: 10.3390/cells12242801. View

Jiang S, Geng S, Chen Q, Zhang C, Cheng M, Yu Y . Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients. Front Oncol. 2022; 12:823705. PMC: 8864310. DOI: 10.3389/fonc.2022.823705. View

Lippenszky L, Mittendorf K, Kiss Z, LeNoue-Newton M, Napan-Molina P, Rahman P . Prediction of Effectiveness and Toxicities of Immune Checkpoint Inhibitors Using Real-World Patient Data. JCO Clin Cancer Inform. 2024; 8:e2300207. PMC: 10919473. DOI: 10.1200/CCI.23.00207. View

Inamura K . Roles of microbiota in response to cancer immunotherapy. Semin Cancer Biol. 2020; 65:164-175. DOI: 10.1016/j.semcancer.2019.12.026. View

Wan L, Wu C, Wu Q, Luo S, Liu J, Xie X . Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients. Cancer Med. 2022; 12(2):1841-1849. PMC: 9883533. DOI: 10.1002/cam4.4994. View

10.

Lu P, Tsai T, Chang J, Deng S, Cheng C . Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia. J Clin Pharm Ther. 2020; 46(2):408-414. DOI: 10.1111/jcpt.13298. View

11.

Xue C, Chu Q, Zheng Q, Yuan X, Su Y, Bao Z . Current understanding of the intratumoral microbiome in various tumors. Cell Rep Med. 2023; 4(1):100884. PMC: 9873978. DOI: 10.1016/j.xcrm.2022.100884. View

12.

Perez-Ruiz E, Jimenez-Castro J, Berciano-Guerrero M, Valdivia J, Estalella-Mendoza S, Toscano F . Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice. Clin Transl Oncol. 2020; 22(10):1778-1785. DOI: 10.1007/s12094-020-02315-9. View

13.

Derosa L, Hellmann M, Spaziano M, Halpenny D, Fidelle M, Rizvi H . Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Ann Oncol. 2018; 29(6):1437-1444. PMC: 6354674. DOI: 10.1093/annonc/mdy103. View

14.

Kim H, Lee J, Hong S, Lee M, Kang J, Kim I . The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer. 2019; 19(1):1100. PMC: 6852740. DOI: 10.1186/s12885-019-6267-z. View

15.

Shah H, Ng T . A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome. Transl Lung Cancer Res. 2023; 12(4):909-926. PMC: 10183407. DOI: 10.21037/tlcr-22-595. View

16.

Ma Y, Deng Y, Shao T, Cui Y, Shen Y . Causal effects of gut microbiota in the development of lung cancer and its histological subtypes: A Mendelian randomization study. Thorac Cancer. 2024; 15(6):486-495. PMC: 10883858. DOI: 10.1111/1759-7714.15220. View

17.

Martinez-Mugica Barbosa C, Cercos Lleti A, Pampin Sanchez R, Duran Roman C, Terroba Alonso P, Fernandez Gonzalez B . Impact of the use of antibiotics on the clinical response to immune checkpoint inhibitors in patients with non-small cell lung cancer. Rev Esp Quimioter. 2022; 35(6):551-558. PMC: 9728602. DOI: 10.37201/req/040.2022. View

18.

Baek Y, Joo Kang E, Hong S, Park S, Kim J, Shin J . Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Int J Cancer. 2021; 150(8):1291-1300. DOI: 10.1002/ijc.33892. View

19.

Kulkarni A, Ebadi M, Zhang S, Meybodi M, Ali A, DeFor T . Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types. ESMO Open. 2020; 5(5):e000803. PMC: 7477978. DOI: 10.1136/esmoopen-2020-000803. View

20.

Chalabi M, Cardona A, Nagarkar D, Dhawahir Scala A, Gandara D, Rittmeyer A . Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials. Ann Oncol. 2020; 31(4):525-531. DOI: 10.1016/j.annonc.2020.01.006. View